Atıf İçin Kopyala
Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...Daha Fazla
PANCREATOLOGY, cilt.20, sa.6, ss.1131-1138, 2020 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
20
Sayı:
6
-
Basım Tarihi:
2020
-
Doi Numarası:
10.1016/j.pan.2020.06.012
-
Dergi Adı:
PANCREATOLOGY
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
-
Sayfa Sayıları:
ss.1131-1138
-
Anahtar Kelimeler:
FOLFIRINOX, Gemcitabine, Nab-paclitaxel, Neoadjuvant chemotherapy, ADJUVANT CHEMOTHERAPY, OPEN-LABEL, GEMCITABINE, FOLFIRINOX, RESECTION, ADENOCARCINOMA, PHASE-3, DEATHS
-
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli:
Evet
Özet
Background: Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis.